オプションチェーンは、Quantum BioPharmaの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Quantum BioPharmaの市場センチメントを評価します。.

Quantum BioPharma (NASDAQ:QNTM) 株価情報, オプションチェーン

Quantum BioPharma

Quantum BioPharma Ltd formerly FSD Pharma Inc is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative, and inflammatory disorders. Along with its subsidiaries, the group is focused on pharmaceutical research and development of its compound, FSD201, an ultra-micronized PEA, for the treatment of inflammatory diseases; Lucid-Psych is used in the treatment of mental health disorders and Lucid-MS is used in the treatment of neurodegenerative disorders. The company operates in two segments: Biopharmaceutical and Strategic Investments.

Quantum Biopharma Ltd. - Class B Subordinate Voting Shares

Quantum BioPharma Ltd

BlackBerry Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BB#NYSE">BB</a>) reported third-quarter financial results after the market close on Thursday. Here&#8217;s a look at the key metrics <a href="https://www.benzinga.com/pressreleases/24/12/ac42605872/blackberry-reports-third-quarter-fiscal-year-2025-results">from the quarter</a>.
Q3 Earnings: BlackBerry reported third-quarter revenue of $162 million. The company reported third-quarter adjusted earnings of two cents per share, beating analyst <a href="https://www.benzinga.com/calendars/earnings">estimates</a> for a loss of one cent per share, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
IoT revenue was&nbsp;$62&nbsp;million, up 13% year-over-year.&nbsp;Cybersecurity revenue totaled $93&nbsp;million in the quarter, up 7% year-over-year. Licensing revenue&nbsp;came in at $7&nbsp;million.
Total company gross margin was 74% in the quarter. Operating cash flow improved by $34 million year-over-year to $3 million. BlackBerry ended the quarter with $266 million in&nbsp;cash, cash equivalents and&nbsp;short-&nbsp;and long-term investments.
&#8220;BlackBerry achieved a significant inflection in its results this past quarter. Driven by a combination of strong revenue performance for both our Cybersecurity and IoT divisions, and continued focus on costs and efficiency, the company delivered stronger than expected profitability and a return to positive cash flow ahead of schedule,&#8221; said John Giamatteo, CEO of BlackBerry. 
From Last Week: <a href="https://www.benzinga.com/24/12/42477300/russian-state-backed-hackers-target-ukrainian-military-devices-via-spacexs-starlink-microsoft-report-reveals">Russian State-Backed Hackers Target Ukrainian Military Devices Via SpaceX&#8217;s Starlink, Microsoft Reveals</a>
Guidance: BlackBerry expects fourth-quarter revenue of $126 million to $135 million versus estimates of $161.49 million. The company anticipates fourth-quarter IoT revenue of $60 million to $65 million, secure communications revenue of $62 million to $66 million and licensing and other revenue of approximately $4 million.
BlackBerry expects full-year revenue of $517 million to $526 million versus estimates of $603.12 million. The company anticipates full-year adjusted earnings to be somewhere between breakeven and a loss of two cents per share, versus estimates for a loss of two cents per share.
Management will further discuss the quarter on a call with investors and analysts at 5:30 p.m. ET.
BB Price Action:&nbsp;<a href="https://www.benzinga.com/quote/BB" target="_blank" rel="noreferrer noopener">BlackBerry shares</a>&nbsp;were up 0.17% in after hours, trading at $2.98 at the time of publication Thursday, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Photo: Courtesy of BlackBerry.

Earnings

News

Movers

Tech

BlackBerry Beats Q3 Earnings Estimates, But Soft Guidance Keeps Shares In Check

Legal

SVCO

Silvaco Says US Court Of Appeals For The Ninth Circuit Affirmed US District Court's Dismissal Of All Claims Brought By Aldini

ALLETE Says FERC Approved Proposed Transaction With CPP Investments And Global Infrastructure Partners

Guidance

PARR

Par Pacific Expects 2025 Capital Expenditure And Turnaround Outlay Guidance Of $210M - $240M

Marsh &amp; McLennan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMC#NYSE">MMC</a>) has outperformed the market over the past 10 years by 2.76% on an annualized basis producing an average annual return of 13.69%. Currently, Marsh &amp; McLennan has a market capitalization of $103.31 billion. 
Buying $100 In MMC: If an investor had bought $100 of MMC stock 10 years ago, it would be worth $360.25 today based on a price of $210.35 for MMC at the time of writing.
<h3>Marsh &amp; McLennan's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734647416_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much $100 Invested In Marsh & McLennan 10 Years Ago Would Be Worth Today

SPRY

ARS Pharmaceuticals Says Express Scripts Has Added neffy (Epinephrine Nasal Spray) To Its Commercial National Formularies

The Stock Repurchase Program will begin on December 19, 2024 and conclude on December 19, 2025.

Buybacks

FRST

Primis Financial Board Approves Stock Repurchase Program For Up To 740,600 Of Outstanding Shares Of Common Stock

As a result of this error, the Bank will record $8.1 million on a pre-tax basis of occupancy expense in the fourth quarter of 2024. On an after-tax basis, this will reduce fourth quarter diluted earnings per share by approximately $0.43.
As for the impact of ASC 842 in future years, it is expected that the correct calculation of lease expense will increase occupancy expense by approximately $1.6 million per year on a pre-tax basis.
It has evaluated the impact to income for each of the periods involved as well as the cumulative impact to 2024's results and have determined the understatement in the prior years as well as the impact to the results for 2024 are not material to the Bank's results of operations or its balance sheet.

PFBC

Preferred Bank Finds Unreconciled Difference In Its Calculation Of Its Right Of Use Asset And Lease Liabilities; Expects Additional Q4 Expense To Reduce Q4 EPS By $0.43

ASAI

Sendas Distribuidora Intends To Proceed With Voluntary Delisting Of Its ADSs From NYSE

BlackBerry (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BB#NYSE">BB</a>) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $(0.01) by 300 percent. This is a 100 percent increase over earnings of $0.01 per share from the same period last year. The company reported quarterly sales of $143.00 million which missed the analyst consensus estimate of $150.76 million by 5.15 percent. This is a 18.29 percent decrease over sales of $175.00 million the same period last year.

BlackBerry Q3 2025 Sales $143.00M Miss $150.76M Estimate

FCPT

Four Corners Property Trust Reports Acquisition Of A MercyOne Outpatient Clinic Property For $2.8M

BlackBerry is providing the following guidance for the fourth quarter and the full fiscal year 2025 (ending February 28, 2025).&nbsp;
As the sale of the Company's Cylance business is expected to close during the fourth quarter of 2024, that business is reported this quarter as discontinued operations, and the following guidance, except for non-GAAP basic EPS, is reflective solely of the expected results of the Company's continuing operations.

BlackBerry Now Expects FY25 Total Revenue Of $517M - $526M (Est $603.12M), Non-GAAP Basic EPS Of $(0.02) - Breakeven (Est $(0.02))

BlackBerry Expects Q4 Total Revenue Of $126M - $135M (Est $161.49M), Non-GAAP Basic EPS Of $(0.01) - $0.01 (Est $0.01)

Arch Capital Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACGL#NASDAQ">ACGL</a>) has outperformed the market over the past 10 years by 5.27% on an annualized basis producing an average annual return of 16.19%. Currently, Arch Capital Group has a market capitalization of $33.48 billion. 
Buying $100 In ACGL: If an investor had bought $100 of ACGL stock 10 years ago, it would be worth $446.81 today based on a price of $88.99 for ACGL at the time of writing.
<h3>Arch Capital Group's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734646508_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACGL

Here's How Much $100 Invested In Arch Capital Group 10 Years Ago Would Be Worth Today

Cohealyx is designed for tissue integration and revascularization to facilitate wound healing, reduce treatment timelines, and improve patient outcomes in the treatment of full-thickness wounds.

RCEL

AVITA Medical Secures FDA 510(k) Clearance For Cohealyx

Exchange-traded funds are rewriting the financial playbook, with 2024 marking a historic <a href="https://www.benzinga.com/etfs">year for the industry.</a>
From record-breaking flows to innovative fund launches, Bank of America detailed $1.6 trillion in ETF inflows this year in a new note. The global ETF market has grown to a staggering $15.1 trillion in assets under management. 
Additionally, ETF launches hit an all-time high of 1,485 in 2024, and institutional ownership continues to surge, cementing ETFs as the cornerstone of modern investment strategies. 
Here's how the ETF ecosystem is evolving — and why it matters.
<h3 class="wp-block-heading">Record Year for ETF Growth</h3>
The numbers speak for themselves: over the last five years, the global ETF market has grown at a robust 19% annualized rate, amassing more than $15 trillion in assets under management. 
In total, 15,866 ETFs have been created since 1993, with 2024 alone contributing 1,485 of those — a record for both active and U.S.-listed ETFs.
Institutional investors, retail traders and even cash-strapped mutual funds are gravitating toward ETFs for their liquidity, tax efficiency and cost advantages.
<h3 class="wp-block-heading">The Rise of Active ETFs: A Balancing Act</h3>
While ETFs have historically been dominated by passive strategies, active ETFs are making their presence known. Active funds accounted for 18% of total inflows in 2024, signaling a growing appetite for alpha strategies.
Still, passive funds remain the kingpin, representing over 50% of equity fund assets by AUM. 
In fact, 93% of ETFs track some type of index, but the allure of active management is pushing innovation. 
Investors seeking more active strategies in passive funds are also driving mutual fund-to-ETF conversions. According to Bank of America, this trend is likely to accelerate in the coming years as mutual funds struggle to remain relevant.
<h3 class="wp-block-heading">SPY vs. VOO: New ETF Champion in the Making?</h3>
The SPDR S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) remains the largest and most actively traded ETF since its inception in 1993. But its throne is being challenged.
Vanguard S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOO#NYSE">VOO</a>) has a 6.5-basis-point lower expense ratio compared to SPY and could potentially surpass it in AUM by 2026.
In 2024, VOO registered more than six times the inflows obtained by SPY. 
<h3 class="wp-block-heading">Fund Flows: The Biggest Winners of 2024</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>ETF</th>
<th>Fund Flows YTD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vanguard S&amp;P 500 ETF (VOO)</td>
<td>$122.75 billion</td>
</tr>
<tr>
<td>iShares Core S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVV#NYSE">IVV</a>)</td>
<td>$48.97 billion</td>
</tr>
<tr>
<td>iShares Bitcoin Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBIT#NYSE">IBIT</a>)</td>
<td>$37.04 billion</td>
</tr>
<tr>
<td>Vanguard Total Stock Market ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTI#NYSE">VTI</a>)</td>
<td>$29.96 billion</td>
</tr>
<tr>
<td>Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)</td>
<td>$25.38 billion</td>
</tr>
<tr>
<td>iShares Core U.S. Aggregate Bond ETF (AGG)</td>
<td>$20.62 billion</td>
</tr>
<tr>
<td>SPDR Portfolio S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPLG#NYSE">SPLG</a>)</td>
<td>$19.91 billion</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Data: TradingView as of Dec. 19, 2024. </figcaption></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42594797/trump-wants-to-get-rid-of-the-debt-ceiling-30-year-treasury-bonds-fall-to-2024-lows-stocks-cut-gains">Trump Would &#8216;Lead The Charge&#8217; To Scrap Debt Ceiling: 30-Year Treasury Bonds Slide To 2024 Lows, Stocks Cut Gains</a></li>
</ul>
Photo via Shutterstock.

Analyst Color

Broad U.S. Equity ETFs

Markets

ETFs

IBIT

SPLG

ETF Market Sets Records In 2024 As Inflows Reach $1.6 Trillion: 7 Funds Leading Charge

United States Steel Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/X#NYSE">X</a>) shares are trading lower in Thursday&#8217;s after-hours session after the company issued fourth-quarter guidance <a href="https://www.benzinga.com/pressreleases/24/12/b42604235/united-states-steel-corporation-provides-fourth-quarter-2024-guidance">below analyst estimates</a>.
What Happened: After the market close on Thursday, U.S. Steel said it expects to report a fourth-quarter adjusted loss of 25 cents to 29 cents per share. Fourth-quarter adjusted EBITDA is expected to come in around $150 million.
&#8220;Steel prices remained depressed and BR2 ramp-related costs exert pressure on the quarter, while the Big River team works towards increasing prime ton production in our new mill. Despite the challenging pricing environment across all segments, the North American Flat-Rolled segment continues to deliver strong EBITDA primarily through its robust commercial strategy and a diverse product mix,&#8221; said David Burritt, CEO of U.S. Steel.
Q4 Adjusted EBITDA By Segment:
<ul>
<li>The Flat-Rolled segment&#8217;s adjusted EBITDA is expected to be lower than the&nbsp;third quarter&nbsp;due to lower selling prices and volumes.</li>
<li>The Mini Mill segment&#8217;s adjusted EBITDA is expected to be lower than the&nbsp;third quarter&nbsp;due to lower volumes.</li>
<li>The European segment&#8217;s adjusted EBITDA is expected to be lower than the&nbsp;third quarter, largely due to the unfavorable impact of weak demand, resulting in lower volumes, average selling prices and volume inefficiencies.</li>
<li>The Tubular segment&#8217;s adjusted EBITDA is expected to be higher than the&nbsp;third quarter, primarily due to increased volume and lower costs due to the absence of outage activity.</li>
</ul>
&#8220;In Europe, the demand and pricing environment remains weak. To meet production volume requirements after unplanned downtime from a fire at the #1 Caster, we are temporarily operating three blast furnaces beginning Dec. 7, but expect to return to two blast furnaces by January. The Tubular segment continues to face pressure from a weak pricing environment,&#8221; Burritt added.
Check This Out: <a href="https://www.benzinga.com/news/earnings/24/12/42605034/fedex-stock-rallies-on-better-than-expected-q2-eps-freight-spin-off-announcement">FedEx Stock Rallies On Better-Than-Expected Q2 EPS, Freight Spin-Off Announcement</a>
U.S. Steel is due to report fourth-quarter financial results near the end of January. Analysts currently expect the company to report fourth-quarter revenue of $3.69 billion. Fourth-quarter earnings were projected around 16 cents per share before Thursday&#8217;s guidance update.
X Price Action: U.S. Steel shares were down 4.54% in Thursday&#8217;s after-hours session, trading at $30.28 at the time of publication, per <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Courtesy U.S. Steel

Commodities

After-Hours Center

US Steel Stock Stumbles On Weak Q4 Outlook

The ASR agreements will be completed under Kroger's recently announced $7.5 billion share repurchase authorization. Kroger is funding the share repurchases under the ASR agreements with existing cash on hand.

Kroger Enters Agreements For $5.0B Accelerated Share Repurchase Program

BlackBerry (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BB#NYSE">BB</a>) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $(0.01) by 300 percent. This is a 100 percent increase over earnings of $0.01 per share from the same period last year.

Earnings Beats

BlackBerry Q3 2025 Adj EPS $0.02 Beats $(0.01) Estimate

Murder suspect Luigi Mangione was extradited from Pennsylvania to New York on Thursday and faced his first federal court appearance after receiving <a href="https://www.benzinga.com/news/legal/24/12/42593013/luigi-mangione-faces-extradition-possible-federal-charges-may-carry-death-penalty">new federal charges.</a>
What Happened: Mangione, who is the <a href="https://www.benzinga.com/general/health-care/24/12/42316904/unitedhealthcare-ceo-brian-thompson-fatally-shot-outside-nyc-hotel">suspect in the murder</a> of UnitedHealthcare CEO Brian Thompson, appeared in a New York federal court Thursday to hear and discuss the four federal counts he now faces in the case.
The federal charges include murder through use of a firearm and stalking, according to <a href="https://www.cnn.com/us/live-news/the-latest-on-the-unitedhealthcare-ceo-killing-suspect-12-19-24/index.html">CNN</a>. Also wanted on state charges in Pennsylvania and New York, Mangione was taken into federal custody around 1 p.m. ET Thursday before being transported to New York.
The unsealed federal complaint showed that the notebook found in Mangione's possession when arrested at the Pennsylvania McDonald's included handwritten pages criticizing the health insurance sector and wealthy executives.
An entry in the notebook dated Aug. 15 said, "The details are finally coming together." The entry said procrastination had allowed Mangione to learn more about the redacted company he was targeting.
"The target is insurance…it checks every box," is also found in the notebook alleged to belong to Mangione, according to the federal complaint.
The notebook also references the investor conference that Thompson was set to attend.
"This investor conference is a true windfall."
Traveling across state lines and the "use of interstate facilities" to carry out the attack led to federal prosecutors claiming jurisdiction in the case.
The UnitedHealthcare CEO was believed to have been targeted by Mangione as the CEO of the insurance unit of UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), one of the largest health insurance companies in the United States, according to the complaint.
On Thursday, Mangione was flown via helicopter from Pennsylvania to New York to meet with his lawyers ahead of the federal court appearance.
Mangione told Magistrate Judge Katharine Parker that he had seen the federal charges and understood what he was accused of.
Mangione's lawyers did not request bail at the Thursday hearing, but noted that they reserve the right to do so in the future.
After the federal court appearance, U.S. Marshals escorted Mangione out of the courtroom.
Mangione will be held in the Metropolitan Detention Center in Brooklyn, the lone New York City federal prison. Rapper Sean "Diddy" Combs is also being held at the same facility awaiting trial on federal charges.
Among the lawyers on Mangione's defense team is Karen Friedman Agnifilo, whose husband, Marc Agnifilo, is representing Diddy.
Read Also: <a href="https://www.benzinga.com/news/legal/24/12/42418763/unitedhealthcare-ceo-murder-suspect-chronic-pain-unabomber-fascination-isolation-details-emerge">UnitedHealthcare CEO Murder Suspect: Chronic Pain, Unabomber Fascination, Isolation Details Emerge</a>
Why It's Important: Thursday's extradition was far from normal course, with New York City Mayor Eric Adams joining the helipad escort of Mangione after the murder suspect arrived in New York.
"This act of terrorism and the violence that stems from (Mangione's case) is something that will not be tolerated in the city. We wanted to personally be here to show the symbolism of leading from the front," Adams told reporters, according to CNN.
Adams said that cheering for Mangione's alleged actions "sends the wrong message" about gun violence.
"You're celebrating using violence to solve an issue."
The public escort by the helipad was unusual for a federal suspect, CNN reported. The very public display of Mangione comes as federal authorities often avoid "perp walks" that can attract supporters and a large media presence. Perp walks can also be viewed as "prejudicial," CNN senior correspondent Evan Pérez said.
What's Next: The federal and state case in New York will "proceed in parallel," the Manhattan District Attorney's office said Thursday, as reported by CNN.
Mangione faces 11 counts in the state of New York, including murder in the first degree, which carries a maximum sentence of prison without parole. The federal charges could see Mangione eligible for the death penalty if convicted of murder.
<a href="https://www.benzinga.com/general/entertainment/24/12/42544499/luigi-mangione-documentaries-in-the-works-from-award-winning-creators-and-possibly-rapper-50-cent">Benzinga recently reported</a> that at least three documentaries are in the works on the life of Mangione and the health insurance industry. ABC, a unit of The Walt Disney Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>), is airing a special edition of &#8220;20/20&#8221; at 10 p.m. ET Thursday. The episode will look at the death of Thompson, the search for Mangione and more on the suspected killer&#8217;s life.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/media/24/12/42473433/joe-rogan-on-public-sympathy-for-unitedhealthcare-ceo-murder-suspect-health-insurance-a-dirty-dirty-business">Joe Rogan On Public Sympathy For UnitedHealthcare CEO Murder Suspect: Health Insurance A &#8216;Dirty, Dirty Business&#8217;</a></li>
</ul>
Photo courtesy of Pennsylvania State Police.

Luigi Mangione's Notebook Reveals Plot, Feds Say: UnitedHealth Group Investor Conference Called 'True Windfall'

11:20 EDT QNTM Stock trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>...

QNTM Stock trading resumes

11:10 EDT QNTM Stock trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time, market-moving breaking...

QNTM Stock trading halted, volatility trading pause

Quantum BioPharma announces through its subsidiary, HUGE Biopharma Australia, that sentinel dosing has started for its trial entitled "A Phase 1, R...

Quantum Group announces start of sentinel dosing in Lucid-21-302 MAD trial

Quantum Biopharma has retained the services of Agoracom, Independent Trading Group, Buyins and Stockjock.com who which will each play a key role in...

Quantum retains services of Agoracom, ITG, Buyins and Stockjock

Quantum Biopharma (TSE:QNTM) has released an update. Quantum Biopharma, formerly known as FSD Pharma Inc., has reported a notable increase in total...

Quantum Biopharma's Financial Growth and Stability

Quantum BioPharma followed up on recent events concerning the complaint filed by the Company in the United States courts, that alleges that CIBC Wo...

Quantum BioPharma invites shareholders to join market manipulation suit

Quantum Biopharma (TSE:QNTM) has released an update. Quantum Biopharma, formerly FSD Pharma, has filed a US$700 million lawsuit against major finan...

Quantum Biopharma Sues Banks for Stock Manipulation

Quantum Biopharma (TSE:QNTM) has released an update. Quantum BioPharma Ltd. announces a non-brokered private placement of convertible debenture uni...

Quantum BioPharma Launches $5 Million Private Placement

Quantum Biopharma (TSE:QNTM) has released an update. Quantum BioPharma's safety review committee has recommended moving forward with dosing the sec...

Quantum BioPharma Advances Lucid-21-302 Clinical Trial

Quantum Biopharma (TSE:QNTM) has released an update. Quantum BioPharma has successfully closed its first tranche of an offering, raising $500,000 t...

Quantum BioPharma Secures Initial Funding Tranche

QNTM

Press Releases

Quantum BioPharma (Nasdaq: QNTM) Files a US Federal Lawsuit Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/Spoofing

Quantum BioPharma Ltd. Alleges Market Manipulation, Files Lawsuit, unbuzzed Continues To Gain Traction

Quantum Biopharma (NASDAQ:QNTM) Posts Link on Its Website to Access the Filed Complaint Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/Spoofing

Freedman Normand Friedland Files Market Manipulation Case On Behalf of Quantum Biopharma

Christian Attar Files Market Manipulation Case On Behalf of Quantum Biopharma

Quantum Biopharma Announces that Sentinel Dosing has Started for the Phase-1 Multiple Ascending Dose Clinical Trial for Lucid-21-302 (Lucid-Ms) in Australia

Quantum BioPharma Previously Known as FSD Pharma (Nasdaq:HUGE) (CSE:HUGE) Invites Shareholders to Come Forward and Join Hands With the Company in the US700M$+ Court Case the Company Has Filed Against CIBC, RBC, and Others for Alleged Spoofing/Stock Price Manipulation

Offerings

Quantum Biopharma Announces Non-Brokered Private Placement of Convertible Debenture Units for Gross Proceeds of Up to $5 Million

Quantum Biopharma Announces That the Safety Review Committee Recommends Commencing Dosing of Second Cohort in the Phase 1 Multiple Ascending Dose Clinical Trial for Lucid-21-302 (Lucid-MS)

Comments

Quantum BioPharma

Quantum BioPharma (QNTM) オプション

Quantum BioPharma (NASDAQ:QNTM) 株価情報, オプションチェーン

ニュース

パートナーシップ

ベンジンガ・グローバル